Objective: The Pirarubicin Monotherapy Study Group trial was a randomized Phase II study that evaluated the efficacy of intravesical instillation of pirarubicin in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. This study conducted further analysis of the Pirarubicin Monotherapy Study Group cohort, focusing on intravesical seeding of cancer cells. Methods: Using the data from the Pirarubicin Monotherapy Study Group trial, bladder recur-rence-free survival rates and factors associated with bladder recurrence in the control group were analyzed. Results: Of 36 patients in the control group, 14 with positive urine cytology had more frequent recurrence when compared with the 22 patient...
Copyright © 2015 Tomonori Kato et al.This is an open access article distributed under the Creative C...
Objectives: To investigate the efficacy of single or double epirubicin instillation during the early...
Context: Bladder recurrences have been reported in 22–47% of patients after surgery for upper urinar...
Objective: The Pirarubicin Monotherapy Study Group trial was a randomized Phase II study that evalua...
Context: The standard management of upper urinary tract urothelial carcinoma (UUT-UC) is nephrourete...
Background Immediate intravesical instillation of chemotherapeutic agents after transurethral resect...
The high incidence of tumor recurrence following transurethral resection (TUR) represents a major pr...
Background: Level 1 evidence supports the administration of single postoperative intravesical chemot...
To date, prophylactic intravesical chemotherapy after radical nephroureterectomy is one of the few a...
Introduction: Intravesical recurrence after treatment of primary upper urinary tract urothelial carc...
Purpose: In this study, we investigated the ability of UroVysionTM to assess response to intravesica...
Background: Following radical nephro-ureterectomy for urothelial carcinoma of the upper urinary trac...
BackgroundUpper urinary tract urothelial carcinoma (UUT-UC) is a rare and severe urinary malignancy....
Non-muscle-invasive bladder cancer (NMIBC) is characterized by a tendency for recurrence and capacit...
Background/purpose: There is currently no consensus about the pattern and risk factors of bladder re...
Copyright © 2015 Tomonori Kato et al.This is an open access article distributed under the Creative C...
Objectives: To investigate the efficacy of single or double epirubicin instillation during the early...
Context: Bladder recurrences have been reported in 22–47% of patients after surgery for upper urinar...
Objective: The Pirarubicin Monotherapy Study Group trial was a randomized Phase II study that evalua...
Context: The standard management of upper urinary tract urothelial carcinoma (UUT-UC) is nephrourete...
Background Immediate intravesical instillation of chemotherapeutic agents after transurethral resect...
The high incidence of tumor recurrence following transurethral resection (TUR) represents a major pr...
Background: Level 1 evidence supports the administration of single postoperative intravesical chemot...
To date, prophylactic intravesical chemotherapy after radical nephroureterectomy is one of the few a...
Introduction: Intravesical recurrence after treatment of primary upper urinary tract urothelial carc...
Purpose: In this study, we investigated the ability of UroVysionTM to assess response to intravesica...
Background: Following radical nephro-ureterectomy for urothelial carcinoma of the upper urinary trac...
BackgroundUpper urinary tract urothelial carcinoma (UUT-UC) is a rare and severe urinary malignancy....
Non-muscle-invasive bladder cancer (NMIBC) is characterized by a tendency for recurrence and capacit...
Background/purpose: There is currently no consensus about the pattern and risk factors of bladder re...
Copyright © 2015 Tomonori Kato et al.This is an open access article distributed under the Creative C...
Objectives: To investigate the efficacy of single or double epirubicin instillation during the early...
Context: Bladder recurrences have been reported in 22–47% of patients after surgery for upper urinar...